Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Mai, Elias K.; Miah, Kaya; Bertsch, Uta; Duerig, Jan; Scheid, Christof; Weisel, Katja C.; Kunz, Christina; Munder, Markus; Lindemann, Hans-Walter; Merz, Maximilian; Hose, Dirk; Jauch, Anna; Seckinger, Anja; Luntz, Steffen; Sauer, Sandra; Fuhrmann, Stephan; Brossart, Peter; Elmaagacli, Ahmet; Goerner, Martin; Bernhard, Helga; Hoffmann, Martin; Raab, Marc S.; Blau, Igor W.; Haenel, Mathias; Benner, Axel; Salwender, Hans J.; Goldschmidt, Hartmut

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Author:

Mai, Elias K.; Miah, Kaya; Bertsch, Uta; Duerig, Jan; Scheid, Christof; Weisel, Katja C.; Kunz, Christina; Munder, Markus; Lindemann, Hans-Walter; Merz, Maximilian; Hose, Dirk; Jauch, Anna; Seckinger, Anja; Luntz, Steffen; Sauer, Sandra; Fuhrmann, Stephan; Brossart, Peter; Elmaagacli, Ahmet; Goerner, Martin; Bernhard, Helga; Hoffmann, Martin; Raab, Marc S.; Blau, Igor W.; Haenel, Mathias; Benner, Axel; Salwender, Hans J.; Goldschmidt, Hartmut

Tübinger Autor(en):

Weisel, Katja

Published in:

Leukemia (2021), Bd. 35, H. 3, S. 809-822

Verlagsangabe:

Springernature

Language:

English

Full text:

http://dx.doi.org/10.1038/s41375-020-0976-9

ISSN:

1476-5551